Company intelligence / Profile preview

Exogene

Oxford, England, United Kingdomexogene.co.uk ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

Exogene is developing a platform that combines generative AI with high-throughput lab experiments to discover novel T-cell receptors for cancer treatment. No specific clinical results are mentioned in the search results.

Therapeutic areas: Oncology
Modalities: TCR-based cell therapies
Industry: Biotech

Partnerships

Plans to partner with pharma and biotech companies

Beyond the preview

Go deeper on Exogene.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exogene.

Explore the full profile